Ligand Reports Second Quarter 2023 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq reaches record high close, AI stocks rally
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Ligand Pharma (LGND) Tops Q2 EPS by 84c
August 8, 2023 4:53 PM EDTLigand Pharma (NASDAQ: LGND) reported Q2 EPS of $1.42, $0.84 better than the analyst estimate of $0.58. Revenue for the quarter came in at $26.4 million versus the consensus estimate of $24.74 million.
GUIDANCE:
Ligand Pharma sees FY2023 EPS of $4.85-$5.00, versus the consensus of... More
